INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

CARCINOGENESIS, published by Oxford University Press, is a premier journal dedicated to the nuanced field of cancer research. With an ISSN of 0143-3334 and an E-ISSN of 1460-2180, this esteemed journal plays a crucial role in disseminating high-quality research findings since its inception in 1980, making it a cornerstone in the exploration of carcinogenic processes. As of 2023, it stands out with a commendable Q2 ranking in Cancer Research and a Q1 ranking in Medicine (miscellaneous), reflecting its significant impact in advancing knowledge in these vital areas. Supported by a strong Scopus ranking, specifically holding the 61st position out of 230 in Biochemistry, Genetics, and Molecular Biology within Cancer Research, CARCINOGENESIS provides researchers, healthcare professionals, and students access to peer-reviewed articles that cover a broad spectrum of topics related to cancer etiology, prevention, and treatment. Although it is not an open-access journal, its commitment to excellence ensures that every published article contributes meaningfully to the global fight against cancer, making it an essential resource for those engaged in cutting-edge cancer research.

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Breast Cancer-Targets and Therapy is a leading journal in the field of oncology, published by DOVE MEDICAL PRESS LTD in New Zealand. Established as an Open Access journal in 2009, it offers a platform for researchers and healthcare professionals to disseminate innovative findings and therapeutic strategies related to breast cancer. With an impressive ranking in the Q2 category of oncology journals as of 2023, and placed at Rank #203/404 in the Scopus database, this journal facilitates the exchange of high-quality research aimed at improving patient outcomes and advancing clinical practices. Covering a wide array of topics from basic research to clinical trials, Breast Cancer-Targets and Therapy plays a crucial role in bridging the gap between scientific discovery and practical application. Researchers, professionals, and students alike will find the journal a valuable resource for the latest advancements and best practices in breast cancer treatment.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.